Skip to main content
. 2018 Mar 5;52(5):1528–1538. doi: 10.3892/ijo.2018.4299

Figure 6.

Figure 6

Increased expression of IL-17A in peripheral blood predicts a worse survival of patients with diffuse large B cell lymphoma (DLBCL). A total of 73 patients with DLBCL (prior to treatment with R-CHOP regimens) were divided into 2 groups according to the median level (54.18 pg/ml) of IL-17A in PB. (A and B) The progression-free survival and overall survival of patients with DLBCL were significantly decreased with the increased expression of IL-17A, as shown by Kaplan-Meier survival analysis plots (P=0.020 and P=0.022). Significance was determined using the log-rank test. Hazard ratio and 95% CI were calculated using the Cox regression.